A 24-week Off Drug Extension Parallel Group Study Assessing the Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind Placebo-controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Bimagrumab (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Jul 2017 Planned number of patients changed from 125 to 200.
- 23 Jul 2017 Planned End Date changed from 21 Aug 2019 to 19 Aug 2019.
- 23 Jul 2017 Planned primary completion date changed from 20 Sep 2018 to 18 Sep 2018.